{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tablet&page=8",
    "query": {
      "intervention": "Tablet",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 11819,
    "total_pages": 1182,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tablet&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tablet&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T18:42:03.657Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03654274",
      "title": "SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 802,
      "start_date": "2018-05-22",
      "completion_date": "2023-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 60,
      "location_summary": "Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654274"
    },
    {
      "nct_id": "NCT01336218",
      "title": "Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2011-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-07-22",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336218"
    },
    {
      "nct_id": "NCT07540897",
      "title": "A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Narcolepsy Type 1"
      ],
      "interventions": [
        {
          "name": "ALKS 2680 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "ALKS 2680 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 150,
      "start_date": "2026-08-13",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 15,
      "location_summary": "Brandon, Florida • Miami, Florida • Winter Park, Florida + 12 more",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07540897"
    },
    {
      "nct_id": "NCT01752413",
      "title": "Iron Depletion and Replacement in Blood Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Ferrous gluconate 325mg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Nutrition counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Blood Centers, Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2012-12",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752413"
    },
    {
      "nct_id": "NCT03709823",
      "title": "Trial of Cytisine in Adult Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Cytisine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        },
        {
          "name": "Behavioral support",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Achieve Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2018-11-13",
      "completion_date": "2019-04-23",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 8,
      "location_summary": "Tempe, Arizona • Burbank, California • Lexington, Kentucky + 5 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709823"
    },
    {
      "nct_id": "NCT03643159",
      "title": "A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Bipolar 1 Disorder",
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Abilify MyCite - Digital Medicine System",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Aripiprazole or other oral antipsychotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "63 Years",
        "sex": "ALL",
        "summary": "18 Years to 63 Years"
      },
      "enrollment_count": 2,
      "start_date": "2018-06-28",
      "completion_date": "2018-10-17",
      "has_results": true,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 5,
      "location_summary": "Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Smyrna",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Fairlawn",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03643159"
    },
    {
      "nct_id": "NCT05433896",
      "title": "Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Drug Interactions"
      ],
      "interventions": [
        {
          "name": "Dasatinib ASD",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 40 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xspray Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2020-11-01",
      "completion_date": "2020-12-19",
      "has_results": false,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 1,
      "location_summary": "Dilworth, Minnesota",
      "locations": [
        {
          "city": "Dilworth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05433896"
    },
    {
      "nct_id": "NCT01172496",
      "title": "A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "treprostinil diethanolamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172496"
    },
    {
      "nct_id": "NCT04100096",
      "title": "A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 332,
      "start_date": "2019-10-17",
      "completion_date": "2021-06-27",
      "has_results": true,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 66,
      "location_summary": "Bentonville, Arkansas • Bellflower, California • Beverly Hills, California + 56 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04100096"
    },
    {
      "nct_id": "NCT03255096",
      "title": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "High-Grade B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "RO6870810",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2017-08-28",
      "completion_date": "2019-07-03",
      "has_results": false,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-10-18T18:42:03.657Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Stanford, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03255096"
    }
  ]
}